NCT07318103

Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention

A Multicentre, Randomised, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Injectable HRS-9057 in Patients With Heart Failure-induced Fluid Retention

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 153 (estimated)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase II clinical study of HRS-9057 injection in patients with heart failure-induced fluid retention

Conditions

• Fluid Retention Caused by Heart Failure

Interventions

Type	Name	Description
DRUG	HRS-9057 injection set	HRS-9057 injection set
DRUG	5% Glucose Injection or 0.9% sodium chloride injection	5% Glucose Injection or 0.9% sodium chloride injection

Timeline

• Start date: 2025-12-31
• Primary completion: 2026-07-01
• Completion: 2026-08-01
• First posted: 2026-01-05
• Last updated: 2026-04-09

Locations

1 site across 1 country: China